BiotechTube

bevacizumab + cyclophosphamide + imatinib

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Unspecified Adult Solid Tumor

Conditions

Unspecified Adult Solid Tumor

Trial Timeline

Aug 1, 2006 → Jan 1, 2011

NCT ID
NCT00390156

About bevacizumab + cyclophosphamide + imatinib

bevacizumab + cyclophosphamide + imatinib is a phase 1 stage product being developed by Novartis for Unspecified Adult Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT00390156. Target conditions include Unspecified Adult Solid Tumor.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00390156Phase 1Completed

Competing Products

20 competing products in Unspecified Adult Solid Tumor

See all competitors
ProductCompanyStageHype Score
DJ-927 + capecitabineDaiichi SankyoPhase 1
33
E7389 + E7389 + E7389EisaiPhase 1
33
bevacizumab + enzastaurin hydrochlorideEli LillyPhase 1
33
SHR-1916Jiangsu Hengrui MedicinePhase 1
33
PembrolizumabMerckPhase 2
52
PI3K inhibitor BKM120 + docetaxelNovartisPhase 1
33
capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)NovartisPhase 1
33
warfarinNovartisPhase 1
33
RLY-1971RochePhase 1
33
Domvanalimab + ZimberelimabGilead SciencesPhase 1
32
BEZ235 + MEK162PfizerPhase 1
32
Utomilumab + ISA101bPfizerPhase 2
51
IrinotecanPfizerPhase 1
32
Ixabepilone + SunitinibPfizerPhase 1
32
ixabepilone + lapatinib ditosylateBristol Myers SquibbPhase 1
32
carboplatin + irinotecan hydrochlorideBristol Myers SquibbPhase 1
32
intoplicineSanofiPhase 1
32
apomineSanofiPhase 1
32
apomineSanofiPhase 1
32
SorafenibBayerPhase 2
49

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85